Cargando…
Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2
BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has sparked investigations to explore the clinical utility of its variants for guiding the development of new diagnostic and therapeutic strategies. However, interpreting the resulting associations into function still remains...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675375/ https://www.ncbi.nlm.nih.gov/pubmed/23617586 http://dx.doi.org/10.1186/1471-2156-14-28 |
_version_ | 1782476079215149056 |
---|---|
author | Howard, Eric W Been, Latonya F Lerner, Megan Brackett, Daniel Lightfoot, Stan Bullen, Elizabeth C Sanghera, Dharambir K |
author_facet | Howard, Eric W Been, Latonya F Lerner, Megan Brackett, Daniel Lightfoot, Stan Bullen, Elizabeth C Sanghera, Dharambir K |
author_sort | Howard, Eric W |
collection | PubMed |
description | BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has sparked investigations to explore the clinical utility of its variants for guiding the development of new diagnostic and therapeutic strategies. However, interpreting the resulting associations into function still remains unclear. Canonical Wnt signaling regulates β-catenin and its binding with TCF7L2, which in turn is critical for the production of glucagon-like peptide-1 (GLP-1). This study examines the role of a novel frame-shift insertion discovered in a conserved region of WNT16a, and it is proposed that this mutation affects T2D susceptibility in conjunction with gene variants in TCF7L2. RESULTS: Our results predicted that the insertion would convert the upstream open reading frame in the Wnt16a mRNA to an alternative, in-frame translation initiation site, resulting in the prevention of nonsense-mediated decay, leading to a consequent stabilization of the mutated WNT16a message. To examine the role of Wnt16a in the Wnt signaling pathway, DNA and serum samples from 2,034 individuals (48% with T2D) from the Sikh Diabetes Study were used in this investigation. Prevalence of Wnt16a insertion did not differ among T2D cases (33%) and controls (32%). However, there was a 3.2 fold increase in Wnt16a mRNA levels in pancreatic tissues from the insertion carriers and a significant increase (70%, p < 0.0001) in luciferase activity in the constructs carrying the insertion. The expression of TCF7L2 mRNA in pancreas was also elevated (~23-fold) among the insertion carriers (p=0.003). CONCLUSIONS: Our results suggest synergistic effects of WNT16a insertion and the at-risk ‘T’ allele of TCF7L2 (rs7903146) for elevating the expression of TCF7L2 in human pancreas which may affect the regulation of downstream target genes involved in the development of T2D through Wnt/β-catenin/TCF7L2 signaling pathway. However, further studies would be needed to mechanistically link the two definitively. |
format | Online Article Text |
id | pubmed-3675375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36753752013-06-08 Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2 Howard, Eric W Been, Latonya F Lerner, Megan Brackett, Daniel Lightfoot, Stan Bullen, Elizabeth C Sanghera, Dharambir K BMC Genet Research Article BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has sparked investigations to explore the clinical utility of its variants for guiding the development of new diagnostic and therapeutic strategies. However, interpreting the resulting associations into function still remains unclear. Canonical Wnt signaling regulates β-catenin and its binding with TCF7L2, which in turn is critical for the production of glucagon-like peptide-1 (GLP-1). This study examines the role of a novel frame-shift insertion discovered in a conserved region of WNT16a, and it is proposed that this mutation affects T2D susceptibility in conjunction with gene variants in TCF7L2. RESULTS: Our results predicted that the insertion would convert the upstream open reading frame in the Wnt16a mRNA to an alternative, in-frame translation initiation site, resulting in the prevention of nonsense-mediated decay, leading to a consequent stabilization of the mutated WNT16a message. To examine the role of Wnt16a in the Wnt signaling pathway, DNA and serum samples from 2,034 individuals (48% with T2D) from the Sikh Diabetes Study were used in this investigation. Prevalence of Wnt16a insertion did not differ among T2D cases (33%) and controls (32%). However, there was a 3.2 fold increase in Wnt16a mRNA levels in pancreatic tissues from the insertion carriers and a significant increase (70%, p < 0.0001) in luciferase activity in the constructs carrying the insertion. The expression of TCF7L2 mRNA in pancreas was also elevated (~23-fold) among the insertion carriers (p=0.003). CONCLUSIONS: Our results suggest synergistic effects of WNT16a insertion and the at-risk ‘T’ allele of TCF7L2 (rs7903146) for elevating the expression of TCF7L2 in human pancreas which may affect the regulation of downstream target genes involved in the development of T2D through Wnt/β-catenin/TCF7L2 signaling pathway. However, further studies would be needed to mechanistically link the two definitively. BioMed Central 2013-04-23 /pmc/articles/PMC3675375/ /pubmed/23617586 http://dx.doi.org/10.1186/1471-2156-14-28 Text en Copyright © 2013 Howard et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Howard, Eric W Been, Latonya F Lerner, Megan Brackett, Daniel Lightfoot, Stan Bullen, Elizabeth C Sanghera, Dharambir K Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2 |
title | Carriers of a novel frame-shift insertion in WNT16a possess elevated
pancreatic expression of TCF7L2 |
title_full | Carriers of a novel frame-shift insertion in WNT16a possess elevated
pancreatic expression of TCF7L2 |
title_fullStr | Carriers of a novel frame-shift insertion in WNT16a possess elevated
pancreatic expression of TCF7L2 |
title_full_unstemmed | Carriers of a novel frame-shift insertion in WNT16a possess elevated
pancreatic expression of TCF7L2 |
title_short | Carriers of a novel frame-shift insertion in WNT16a possess elevated
pancreatic expression of TCF7L2 |
title_sort | carriers of a novel frame-shift insertion in wnt16a possess elevated
pancreatic expression of tcf7l2 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675375/ https://www.ncbi.nlm.nih.gov/pubmed/23617586 http://dx.doi.org/10.1186/1471-2156-14-28 |
work_keys_str_mv | AT howardericw carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 AT beenlatonyaf carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 AT lernermegan carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 AT brackettdaniel carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 AT lightfootstan carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 AT bullenelizabethc carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 AT sangheradharambirk carriersofanovelframeshiftinsertioninwnt16apossesselevatedpancreaticexpressionoftcf7l2 |